Forte Biosciences, Inc. (FBRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $76.99
- As of
Kresmion compiles this page from FBRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Forte Biosciences, Inc. (FBRX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-27.
See the full FBRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for FBRX on one page. Preview it with sample data, then open it live with a free account.
Preview the FBRX dossierActive signals for FBRX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 8.2%, EPS $-0.97 vs $-0.8961 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3402% to FBRX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +94% to FBRX (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 51% of FBRX (2026Q1)
- mediumEARNINGS_MISS
Missed consensus by 41.4% - EPS $-1.37 vs $-0.969 estimate
FREE, NO ACCOUNT
Every signal on FBRX, as it fires
You are seeing 5 of 8 signals recorded on FBRX since 2026-05-16.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FBRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 34962G208 · 2026Q2 | $13.9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 34962G208 · 2026Q2 | $11.6M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 34962G208 · 2026Q2 | $285K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FBRX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
FBRX against its peers
FBRX's return on equity of -113.7% ranks in the 15th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | FBRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 87.3M | n/a | 16 |
| Operating margin | n/a | -141.4% | n/a | 15 |
| Net margin | n/a | -123.1% | n/a | 16 |
| Return on equity | -113.7% | -35.8% | 15 | 16 |
| 1 year | n/a | -5.2% | n/a | 17 |
Peers (19): NTLA, STOK, QURE, CMPS, ABSI, RARE, SEPN, IMCR, VIR, MAZE, ZBIO, URGN, RAPP, BHVN, XNCR, ZYME, MESO, AGIO, SRPT. Left out: BRVE (no annual filing), KLRA (no annual filing), GENB (no annual filing), KALV (no annual filing), COAG (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (FBRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow FBRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to FBRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.